Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390.
The phenylbenzazepine derivative, SCH 23390 was found to be a potent inhibitor of 3H-piflutixol binding to calf striatal dopamine D1 receptors. In contrast SCH 23390 was only a weak inhibitor of 3H-spiperone binding to dopamine D2 receptors. Although possessing some activity at serotonin S2 and alpha 2 adrenergic receptors, SCH 23390 appears to be a potent and selective D1 receptor antagonist.
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D001667:Binding, Competitive; D002417:Cattle; D003342:Corpus Striatum / Q000378:metabolism*; D066298:In Vitro Techniques; D018377:Neurotransmitter Agents / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D017447:Receptors, Dopamine D1; D013134:Spiperone / Q000378:metabolism; D013892:Thioxanthenes / Q000494:pharmacology
D001552:Benzazepines; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D013892:Thioxanthenes; D013134:Spiperone; C015448:piflutixol